Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDIP transferase opposite strand, pseudogene (CDIPTOSP), also known as CDIPT-AS1 and several other aliases, is classified as a human long non-coding RNA pseudogene. Unlike protein-coding genes or validated lncRNAs with clear biological functions, CDIPTOSP has not been shown to express a protein product or serve as a direct therapeutic target. Some evidence of disease association exists, including connections to hepatocellular carcinoma and brain germinoma, but the mechanistic basis of these associations remains uncharacterized. As with most pseudogenes, CDIPTOSP may have regulatory or epigenetic roles that are largely unexplored. There are no known drugs that interact with this gene, no direct molecular mechanism of action, and it is not an established biomarker or source of safety concern in therapeutic development.
None established; pseudogenes generally lack protein products and drug-binding capacity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDIP transferase opposite strand, pseudogene (CDIPTOSP).